# Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

> **NCT05580354** · PHASE4 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Non-muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** BCG combined with Tislelizumab

## Key facts

- **NCT ID:** NCT05580354
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-09
- **Primary completion:** 2024-10-09
- **Final completion:** 2025-05-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580354, "Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT05580354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*